Stock AGN ARGENICA THERAPEUTICS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

News Argenica Therapeutics Limited

Equities

AGN

AU0000150328

Market Closed - Australian S.E.
Other stock markets
 07:10:11 03/05/2024 BST 		5-day change 1st Jan Change
0.585 AUD 0.00% Intraday chart for Argenica Therapeutics Limited +4.46% +14.71%
04-16 Euroz Hartleys Adjusts Argenica Therapeutics’ Price Target to AU$1.40 From AU$1.50, Keeps at Speculative Buy MT
04-12 Argenica Therapeutics Raises AU$12 Million via Placement MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Euroz Hartleys Adjusts Argenica Therapeutics’ Price Target to AU$1.40 From AU$1.50, Keeps at Speculative Buy
MT
Argenica Therapeutics Raises AU$12 Million via Placement
MT
Argenica Therapeutics Doses First Batch of Patients for Phase Two Stroke Trial
MT
Argenica Therapeutics Doses First Patient in Phase Two Stroke Trial; Shares Rally 14%
MT
FDA Grants Argenica Rare Pediatric Disease Designation for Hypoxic Ischaemic Encephalopathy Treatment; Shares Up 16%
MT
Argenica Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023
CI
Argenica Therapeutics Concludes Manufacturing, Release Testing for Stroke Drug; Shares Rise 3%
MT
Argenica Therapeutics On Track for First Patient Dosing in Phase 2 ARG-007 Trial in Q1 2024
MT
AusBiotech energised by new Board appointments
AQ
Argenica Therapeutics Appoints Nonexecutive Chair
MT
Argenica Therapeutics Limited Announces Changes to its Board, Effective 1 December 2023
CI
Argenica Therapeutics Secures US FDA Orphan Drug Designation for Neurological Medication
MT
Argenica Therapeutics Secures AU$2 Million R&D Tax Rebate for Fiscal Year 2023
MT
Argenica Therapeutics Limited Announces the Resignation of Dr. Samantha South as Executive Director Effective 30 November 2023
CI
Argenica Therapeutics' Drug Candidate Reduces Brain Injury in Hypoxic-Ischemic Encephalopathy Preclinical Model
MT
Argenica Therapeutics Secures Ethics Approval for Phase 2 Stroke Trial
MT
Argenica Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023
CI
Preclinical Data Shows Argenica Therapeutics' ARG-007 Able to Mitigate Neurodegenerative Disorders
MT
Argenica Therapeutics Files Ethics Application for Phase Two Stroke Trial
MT
Argenica Therapeutics Validates Efficacy of Neuroprotective Drug in Preclinical Trial
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AGN Stock
  4. News Argenica Therapeutics Limited